CELLAVISION
LIVE

Serial Number

79253926

Owner

CELLAVISION AB

Attorney

Todd Deveau

Filing Date

Nov 13, 2018

Add to watchlist:

No watchlists yet
View on USPTO

CELLAVISION Trademark

Serial Number: 79253926 • Registration: 5986776

CELLAVISION is a trademark filed by CELLAVISION AB on November 13, 2018. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment). The application is currently registered and active.

Owner Contact Info

CELLAVISION AB (11 trademarks)

LUND SE-22362 , SE

Entity Type: 09

Trademark Details

Filing Date

November 13, 2018

Registration Date

February 18, 2020

Published for Opposition

December 3, 2019

Goods & Services

Education services, namely, training and teaching in the field of science, technology, hematology analysis, cytology analysis and the morphology of blood cells and techniques for medical diagnostic analysis of body fluid samples and blood smears

Data processing equipment, computers and computer programs used for medical analysis; laboratory instruments for medical analysis in the nature of medical laboratory research instruments, namely, automated cell locating devices for counting and analyzing blood cells and other blood components for diagnostic purposes, principally comprising a microscope, camera, feeder device for slides or containers containing the blood samples, and computer hardware and downloadable or recorded software for analysis of the samples, all sold as a unit

Computerized medical instruments for medical analysis of body fluids and blood smears; medical apparatus, sold as one unit, for hematology analysis and cytology analysis, composed of disposable cuvettes, medical apparatus used in connection with the staining of patient fluid and tissue samples, including staining fluids for clinical medical use; image reading unit for medical apparatus for sample analysis and diagnosis, namely, image capture units consisting of a two-dimensional sensor with lenses and a source of light; apparatus for mechanic positioning of fluids and samples, namely, pipettes for medical purposes; sample switching apparatus for blood sample analysis for medical diagnostic use

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Sep 22, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Sep 22, 2025 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 22, 2025 APRE
TEAS SECTION 71 & 15 RECEIVED
Jun 20, 2025 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 18, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jul 27, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 10, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 19, 2020 FICS
FINAL DISPOSITION PROCESSED
Jun 19, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 18, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 18, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 13, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 29, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 24, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 24, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 24, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 24, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 4, 2019 CRFA
ASSIGNED TO LIE
Oct 3, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 26, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 9, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 9, 2019 REAP
REFUSAL PROCESSED BY IB
Apr 19, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 30, 2019 RFCS
REFUSAL PROCESSED BY MPU
Mar 30, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 21, 2019 RFCR
NON-FINAL ACTION WRITTEN
Mar 20, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 16, 2019 MAFR
ASSIGNED TO EXAMINER
Mar 12, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 12, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 7, 2019 REPR